Orient Bio (002630.KS) Stock Price

Orient Bio Price

CLOSED
1,443.00
​
Market closed

Over the last 19 years Orient Bio grew revenue by 1.5% annually, reaching 29.75 B KRW. Earnings per share have grown at 20.7% per year over the last 17 years. For Orient Bio, the net margin of -15.3% is down versus 130.1% a few years ago.

Orient Bio stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Orient Bio business model & stock analysis

Orient Bio Inc generates revenue through the production and supply of laboratory animals such as mice, rats, guinea pigs, hamsters, SPF rabbits, and beagles. The company also offers CRO services including safety assessments and new drug development, alongside medical and library equipment like barrier systems. Additional income comes from support services such as rodent surgery, laboratory diagnostics, transgenic services, and genetic testing. The firm further provides feeds, reagents, disinfectants, automobile components, power supply equipment, and other machines through its subsidiaries. Orient Bio Inc's primary customers include research institutions, pharmaceutical companies, and medical facilities requiring laboratory animals and specialized services. The company's product segments consist of live animals, CRO services, medical equipment, and ancillary products like feeds and reagents. Subsidiaries contribute to revenue by supplying complementary items such as disinfectants and power supply equipment. The business model leverages a diversified portfolio of biotechnology products and services, targeting both direct research and development needs and ancillary support requirements. Revenue streams are derived from the sale of animals, provision of CRO services, equipment sales, and subsidiary product lines, ensuring steady income across multiple segments.

Frequently asked questions about Orient Bio

5 analysts currently rate the Orient Bio stock: 4 recommend buying, 1 holding and 0 selling.

Converted at the current exchange rate, the Orient Bio share trades at 0.97 EUR (1,443.00 KRW).

The revenue of Orient Bio is 29.75 B KRW. This figure is based on current financial data and reflects the company's business performance.

The profit of Orient Bio is -4.57 B KRW. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Orient Bio is currently -37.46. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Orient Bio stock.

The price-to-sales ratio (P/S) of Orient Bio is currently 5.75. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Orient Bio stock.

The Eulerpool Quality Score for Orient Bio is 1/10.

The ISIN of Orient Bio is KR7002630002. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Orient Bio is 002630.KS. The ticker symbol is used to trade Orient Bio shares on the stock exchange.

Fair ValueTerminal
1,385.28 KRW
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Life Sciences Tools & Services
Number of shares
Employees
Revenue per Employee
247.95 M KRW
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
South Korea
Currency
KRW
Initial public offering
Dec 28, 1976
ISIN
KR7002630002
Cusip
Y6580S106
Market capitalization
171.09 B KRWLarge Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
2.50
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-6.66 %
Last updated Oct 21, 2026, 5:51 AM

Orient Bio Peer Group

Orient Bio FIGI

002630:KS · BBG000BDR5L4002630:KP · BBG000BDR5X1

All fundamentals and in-depth analysis of Orient Bio

Our stock analysis for Orient Bio stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Orient Bio. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.